Profile data is unavailable for this security.
About the company
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of targeted therapies for women's cancers. Its lead product candidate, OP-1250, is an oral therapy with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). The Company's OP-1250 is an oral small molecule clinical-stage product candidate for the treatment of endocrine-driven cancers. OP-1250, both as a monotherapy and in combination with inhibitors of cyclin-dependent kinase four and six (CDK4/6) demonstrated robust tumor shrinkage in several xenograft models, including ESR1 and PIK3CA mutations and central nervous system (CNS), metastasis. It is in the Phase I/ II clinical trial, and in Phase Ib/ II combination with palbociclib, in patients with metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.
- Revenue in USD (TTM)0.00
- Net income in USD-109.63m
- Incorporated2006
- Employees80.00
- LocationOlema Pharmaceuticals Inc780 Brannan StreetSAN FRANCISCO 94103United StatesUSA
- Phone+1 (415) 651-3316
- Fax+1 (302) 674-5266
- Websitehttps://olema.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astria Therapeutics Inc | 0.00 | -93.24m | 648.89m | 59.00 | -- | 2.51 | -- | -- | -2.30 | -2.30 | 0.00 | 6.32 | 0.00 | -- | -- | 0.00 | -32.43 | -64.48 | -33.78 | -68.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.62 | -- | -- | -- |
| Exscientia PLC (ADR) | 27.66m | -170.55m | 650.15m | 483.00 | -- | 1.64 | -- | 23.50 | -1.34 | -1.34 | 0.2177 | 3.07 | 0.042 | -- | 26.88 | 57,274.49 | -25.87 | -- | -29.52 | -- | -32.45 | -- | -616.50 | -- | -- | -- | 0.0674 | -- | -26.24 | -- | -22.94 | -- | -- | -- |
| Scholar Rock Holding Corp | 0.00 | -203.85m | 659.47m | 150.00 | -- | 4.93 | -- | -- | -2.22 | -2.22 | 0.00 | 1.67 | 0.00 | -- | -- | 0.00 | -79.66 | -38.14 | -89.70 | -44.31 | -- | -- | -- | -647.95 | -- | -- | 0.2726 | -- | -100.00 | -- | -23.26 | -- | -45.61 | -- |
| Adaptive Biotechnologies Corp | 168.77m | -213.47m | 682.80m | 709.00 | -- | 2.83 | -- | 4.05 | -1.47 | -1.47 | 1.16 | 1.64 | 0.2501 | 4.74 | 5.03 | 238,033.80 | -31.65 | -19.69 | -36.63 | -22.06 | 54.77 | 67.18 | -126.55 | -122.27 | 3.84 | -- | 0.3536 | -- | -8.11 | 25.06 | -12.52 | -- | 11.11 | -- |
| MBX Biosciences Inc | 0.00 | -47.20m | 684.85m | 36.00 | -- | -- | -- | -- | -1.48 | -1.48 | 0.00 | 1.71 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.60 | -- | -- | -- |
| ProKidney Corp | 0.00 | -38.68m | 692.32m | 163.00 | -- | -- | -- | -- | -0.5905 | -0.5905 | 0.00 | -7.73 | 0.00 | -- | -- | 0.00 | -27.97 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0003 | -- | -- | -- | 67.17 | -- | -- | -- |
| Rapport Therapeutics Inc | -100.00bn | -100.00bn | 695.32m | 58.00 | -- | 2.06 | -- | -- | -- | -- | -- | 9.21 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -226.57 | -- | -- | -- |
| Olema Pharmaceuticals Inc | 0.00 | -109.63m | 702.66m | 80.00 | -- | 3.09 | -- | -- | -2.06 | -2.06 | 0.00 | 3.97 | 0.00 | -- | -- | 0.00 | -50.73 | -30.06 | -56.10 | -31.40 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.76 | -- | -- | -- |
| Wave Life Sciences Ltd | 110.50m | -73.74m | 712.25m | 266.00 | -- | -- | -- | 6.45 | -0.5796 | -0.5796 | 0.9275 | 0.0359 | 0.5036 | -- | -- | 415,413.50 | -33.49 | -56.98 | -117.16 | -102.38 | -- | -- | -66.50 | -353.20 | -- | -- | 0.00 | -- | 3,005.10 | 51.04 | 64.46 | -- | -35.44 | -- |
| ORIC Pharmaceuticals Inc | 0.00 | -110.78m | 712.48m | 107.00 | -- | 2.26 | -- | -- | -1.76 | -1.76 | 0.00 | 4.47 | 0.00 | -- | -- | 0.00 | -35.69 | -33.92 | -37.77 | -35.77 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.99 | -- | 10.09 | -- |
| Ironwood Pharmaceuticals, Inc. | 400.57m | 9.21m | 715.63m | 267.00 | 103.68 | -- | 77.61 | 1.79 | 0.0432 | 0.0432 | 2.43 | -2.01 | 0.8021 | -- | 4.52 | 1,500,244.00 | 1.44 | -4.54 | 2.21 | -5.20 | -- | -- | 1.79 | -7.81 | -- | 4.60 | 2.07 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
| Savara Inc | 0.00 | -75.29m | 729.18m | 37.00 | -- | 6.02 | -- | -- | -0.4317 | -0.4317 | 0.00 | 0.7361 | 0.00 | -- | -- | 0.00 | -58.02 | -36.86 | -62.14 | -39.54 | -- | -- | -- | -102,587.50 | -- | -- | 0.2066 | -- | -- | -- | -43.38 | -- | 15.91 | -- |
| Annexon Inc | 0.00 | -115.16m | 738.52m | 71.00 | -- | 2.04 | -- | -- | -1.22 | -1.22 | 0.00 | 3.42 | 0.00 | -- | -- | 0.00 | -36.04 | -44.06 | -38.13 | -46.93 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.43 | -- | 62.56 | -- |
| Replimune Group Inc | 0.00 | -220.01m | 753.59m | 331.00 | -- | 1.77 | -- | -- | -3.27 | -3.27 | 0.00 | 6.24 | 0.00 | -- | -- | 0.00 | -38.64 | -29.08 | -41.09 | -30.56 | -- | -- | -- | -- | -- | -- | 0.143 | -- | -- | -- | -23.82 | -- | 16.84 | -- |
Data as of Sep 18 2024. Currency figures normalised to Olema Pharmaceuticals Inc's reporting currency: US Dollar USD
62.45%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BVF Partners LPas of 30 Jun 2024 | 9.14m | 15.95% |
| Paradigm BioCapital Advisors LPas of 01 Aug 2024 | 5.50m | 9.61% |
| Deep Track Capital LPas of 30 Jun 2024 | 4.00m | 6.99% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 3.47m | 6.07% |
| Point72 Asset Management LPas of 30 Jun 2024 | 3.21m | 5.61% |
| Logos Global Management LPas of 30 Jun 2024 | 3.21m | 5.60% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 2.66m | 4.65% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 1.95m | 3.40% |
| Dimensional Fund Advisors LPas of 30 Jun 2024 | 1.56m | 2.72% |
| Geode Capital Management LLCas of 30 Jun 2024 | 1.06m | 1.85% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
